Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ: PROK )

2.255 +0.015 (+0.67%)
Streaming Delayed Price Updated: 10:06 AM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProKidney Corp. - Class A Ordinary Shares

ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
From ProKidney
Via GlobeNewswire
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the Jefferies Global Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
From ProKidney
Via GlobeNewswire
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
From ProKidney
Via GlobeNewswire
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
From ProKidney
Via GlobeNewswire
ProKidney to Participate in Jefferies Biotech on the Bay Summit
From ProKidney
Via GlobeNewswire
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
Former CEO of Africa Healthcare Network brings extensive understanding of kidney disease to ProKidney 
From ProKidney
Via GlobeNewswire
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
From ProKidney
Via GlobeNewswire
ProKidney Reports Third Quarter Financial Results
From ProKidney
Via GlobeNewswire
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
From ProKidney
Via GlobeNewswire
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023
Total of 6 abstracts accepted for publication in Kidney Week 2023 program 
From ProKidney
Via GlobeNewswire
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
From ProKidney
Via GlobeNewswire
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
From ProKidney
Via GlobeNewswire
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
From ProKidney
Via GlobeNewswire
ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
From ProKidney
Via GlobeNewswire
ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
From ProKidney
Via GlobeNewswire
ProKidney to Present at the BofA Securities Health Care Conference 2023
From ProKidney
Via GlobeNewswire
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
From ProKidney
Via GlobeNewswire
ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference
From ProKidney
Via GlobeNewswire
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
From ProKidney
Via GlobeNewswire
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
From ProKidney
Via GlobeNewswire
ProKidney to Participate in Upcoming Investor Conferences
From ProKidney
Via GlobeNewswire
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
From ProKidney
Via GlobeNewswire
ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022
From ProKidney
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.